Amsterdam, Netherlands–(Newsfile Corp. – May 19, 2025) – Neurocast.ai, a digital health company transforming brain health monitoring, has officially registered its passive monitoring platform with the U.S. Food and Drug Administration (FDA) under a 510(k)-exempt classification. This milestone enables Neurocast to bring its breakthrough technology to the U.S. market, starting with multiple sclerosis (MS).
Image 1
To view an enhanced version of this graphic, please visit:
Article Source
https://www.biospace.com/press-releases/neurocast-ai-completes-fda-device-registration-unlocking-u-s-launch-of-brain-health-platform
